Compare Genuine Parts Company (GPC) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs Zoetis Inc — how do they compare? Genuine Parts Company trades at $133.85 (market cap $18.62B), while Zoetis Inc trades at $73.36 (market cap $31.14B). The key difference: Zoetis Inc is the larger of the two by market cap, and Genuine Parts Company pays the higher dividend (3.15%). Which is the better fit depends on your goals.
| GPC | ZTS | |
|---|---|---|
Market Cap | $18.62B | $31.14B |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $156.76 |
52-Week Low | $92.47 | $71.91 |
Enterprise Value | $24.72B | $38.70B |
Dividend Yield | 3.15% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $133.47, down 0.8% today, with a bullish technical trend and strong institutional support. Recent Q2 2026 earnings beat estimates with EPS of $2.15 versus $2.08 expected, driven by 6% sales growth. The stock is near its 52-week high, supported by a consensus price target of $148.67, though net income margins remain thin at 0.13%.
Outlook is positive with analyst consensus leaning buy, but risks include compressed profitability and high P/E ratio. The dividend yield adds income appeal, yet margin pressures from inflation and competition warrant caution for growth-focused investors.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
